Study of two drugs and radiation for triple-negative breast cancer that spread to the brain
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests adding the drugs sacituzumab govitecan and zimberelimab to targeted radiation therapy for people with triple-negative breast cancer that has spread to the brain. The goal is to see if this combination helps control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have triple-negative breast cancer that has spread to the brain, with brain tumors visible on an MRI or confirmed by biopsy.
- You are eligible for a type of focused radiation called stereotactic radiosurgery (SRS) for the brain tumors.
- You have had prior treatment with chemotherapy that included taxane and anthracycline drugs.
- You are not pregnant, not breastfeeding, and willing to use contraception if needed.
- You do not have certain other medical conditions like active autoimmune disease, uncontrolled heart problems, or a history of lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial tests combining stereotactic radiation therapy with immunotherapy (adebrelimab) and chemotherapy (nab-paclitaxel and carboplatin) before surgery for early or locally advanced triple-negative breast cancer. The goal is to see if this combination improves treatment response.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
This study tests whether abemaciclib (a targeted pill) given with focused radiation to brain tumors can control hormone receptor–positive, HER2-negative breast cancer in the brain. It’s designed to see if the combination helps shrink or slow the growth of brain metastases while keeping side effects manageable.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.